Compare Stocks: ATRA, ORIC, IRD, and AGEN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$6.51 +1.7%	$7.70	$2.71 ▼ $10.31	$289.04M	1.31	1.11 million shs	553,852 shs
ATRA Atara Biotherapeutics	$9.43 +0.9%	$9.26	$3.92 ▼ $19.15	$93.85M	0.21	34,212 shs	23,008 shs
IRD Opus Genetics	$3.82 -7.1%	$4.52	$1.70 ▼ $7.07	$340.10M	0.62	1.77 million shs	894,054 shs
ORIC Oric Pharmaceuticals	$13.63 -1.6%	$12.94	$7.23 ▼ $14.68	$1.44B	0.99	1.56 million shs	1.15 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+1.72%	-2.54%	-25.17%	+8.86%	+60.74%
ATRA Atara Biotherapeutics	+0.86%	-2.28%	+5.60%	+19.37%	-35.54%
IRD Opus Genetics	-7.06%	-5.68%	-25.97%	+24.03%	+95.90%
ORIC Oric Pharmaceuticals	-1.59%	+6.73%	+0.96%	+12.64%	+12.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$6.51 +1.7%	$7.70	$2.71 ▼ $10.31	$289.04M	1.31	1.11 million shs	553,852 shs
ATRA Atara Biotherapeutics	$9.43 +0.9%	$9.26	$3.92 ▼ $19.15	$93.85M	0.21	34,212 shs	23,008 shs
IRD Opus Genetics	$3.82 -7.1%	$4.52	$1.70 ▼ $7.07	$340.10M	0.62	1.77 million shs	894,054 shs
ORIC Oric Pharmaceuticals	$13.63 -1.6%	$12.94	$7.23 ▼ $14.68	$1.44B	0.99	1.56 million shs	1.15 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+1.72%	-2.54%	-25.17%	+8.86%	+60.74%
ATRA Atara Biotherapeutics	+0.86%	-2.28%	+5.60%	+19.37%	-35.54%
IRD Opus Genetics	-7.06%	-5.68%	-25.97%	+24.03%	+95.90%
ORIC Oric Pharmaceuticals	-1.59%	+6.73%	+0.96%	+12.64%	+12.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.50	Moderate Buy	$24.50	276.34% Upside
ATRA Atara Biotherapeutics	2.50	Moderate Buy	$9.50	0.74% Upside
IRD Opus Genetics	2.89	Moderate Buy	$12.71	232.83% Upside
ORIC Oric Pharmaceuticals	2.81	Moderate Buy	$21.17	55.29% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, IRD, and AGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	AGEN Agenus	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/22/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
10/16/2026	IRD Opus Genetics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$17.00
10/15/2026	IRD Opus Genetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$23.00 ➝ $26.00
10/8/2026	AGEN Agenus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)
10/6/2026	IRD Opus Genetics	JonesTrading Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$10.00 ➝ $17.00
10/5/2026	AGEN Agenus	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$40.00
10/5/2026	ORIC Oric Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$26.00
10/2/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$114.20M	2.57	N/A	N/A	($8.17) per share	-0.80
ATRA Atara Biotherapeutics	$120.77M	0.78	$4.91 per share	1.92	($5.34) per share	-1.77
IRD Opus Genetics	$14.20M	22.23	N/A	N/A	$0.22 per share	17.36
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	$120K	$2.58	2.52	N/A	N/A	69.33%	-47.68%	57.73%	11/9/2026 (Estimated)
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	6.83	N/A	-269.42%	N/A	-73.01%	10/29/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	N/A	-150.13%	11/11/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)

Latest ATRA, ORIC, IRD, and AGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ORIC Oric Pharmaceuticals	-$0.3836	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	ATRA Atara Biotherapeutics	-$0.1328	N/A	N/A	N/A	$0.80 million	N/A
11/11/2026	Q3 2026	IRD Opus Genetics	-$0.14	N/A	N/A	N/A	$1.55 million	N/A
11/9/2026	Q3 2026	AGEN Agenus	$0.02	N/A	N/A	N/A	$28.20 million	N/A
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/7/2026	Q2 2026	AGEN Agenus	$0.05	-$0.01	-$0.06	-$0.01	$34.00 million	$34.52 million
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.34	0.34
ATRA Atara Biotherapeutics	N/A	1.98	1.98
IRD Opus Genetics	N/A	12.19	12.19
ORIC Oric Pharmaceuticals	N/A	13.19	13.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
ATRA Atara Biotherapeutics	70.90%
IRD Opus Genetics	14.97%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	6.50%
ATRA Atara Biotherapeutics	41.20%
IRD Opus Genetics	11.70%
ORIC Oric Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	81	45.16 million	42.23 million	Optionable
ATRA Atara Biotherapeutics	10	10.04 million	5.90 million	No Data
IRD Opus Genetics	28	82.65 million	72.98 million	Optionable
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable

ATRA, ORIC, IRD, and AGEN Headlines

Recent News About These Companies

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

50 minutes ago | globenewswire.com

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

50 minutes ago | globenewswire.com

Oric Pharmaceuticals (NASDAQ:ORIC) Stock: Insider Dominic Piscitelli Sells 14,000 Shares

October 22 at 5:07 AM | insidertrades.com

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company Stock

October 21 at 7:07 PM | marketbeat.com

Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 10.06%

October 20 at 12:41 AM | aaii.comA

ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026

October 20 at 12:41 AM | finance.yahoo.com

ORIC Pharmaceuticals stock gains 12.10 percent at EUR 12.32

October 20 at 7:41 PM | ad-hoc-news.deA

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

October 19, 2026 | globenewswire.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% After Analyst Upgrade

October 17, 2026 | americanbankingnews.com

JPMorgan raises target for ORIC Pharmaceuticals stock to USD 26.00

October 16, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) Stock

October 16, 2026 | americanbankingnews.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% on Analyst Upgrade

October 15, 2026 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $26.00

October 14, 2026 | marketbeat.com

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 78.13% Potential Upside

October 9, 2026 | directorstalkinterviews.com

Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?

October 8, 2026 | finance.yahoo.com

ORIC(R) Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

October 6, 2026 | marketscreener.comM

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.6% - Here's What Happened

October 6, 2026 | marketbeat.com

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

October 5, 2026 | globenewswire.com

Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated by Analysts at Leerink Partners

October 5, 2026 | marketbeat.com

Oric Pharmaceuticals Director Richard Heyman Files Form 144 to Sell 8,100 Shares

October 3, 2026 | kalkinemedia.comK

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATRA, ORIC, IRD, and AGEN Company Descriptions

Agenus NASDAQ:AGEN

$6.51 +0.11 (+1.72%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$6.48 -0.03 (-0.48%)

As of 10/22/2026 07:50 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Atara Biotherapeutics NASDAQ:ATRA

$9.43 +0.08 (+0.86%)

As of 10/22/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Opus Genetics NASDAQ:IRD

$3.82 -0.29 (-7.06%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$3.80 -0.02 (-0.65%)

As of 04:00 AM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Oric Pharmaceuticals NASDAQ:ORIC

$13.63 -0.22 (-1.59%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$14.24 +0.61 (+4.46%)

As of 04:04 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, IRD, and AGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATRA, ORIC, IRD, and AGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATRA, ORIC, IRD, and AGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATRA, ORIC, IRD, and AGEN Company Descriptions

Agenus NASDAQ:AGEN

Atara Biotherapeutics NASDAQ:ATRA

Opus Genetics NASDAQ:IRD

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, IRD, and AGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATRA, ORIC, IRD, and AGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATRA, ORIC, IRD, and AGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATRA, ORIC, IRD, and AGEN Company Descriptions

Agenus NASDAQ:AGEN

Atara Biotherapeutics NASDAQ:ATRA

Opus Genetics NASDAQ:IRD

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools